Abstract
Abstract
Background
Adding risk stratification to standard screening via the NHS Breast Screening Programme (NHSBSP) allows women at higher risk to be offered additional prevention and screening options. It may, however, introduce new harms such as increasing cancer worry. The present study aimed to assess whether there were differences in self-reported harms and benefits between women offered risk stratification (BC-Predict) compared to women offered standard NHSBSP, controlling for baseline values.
Methods
As part of the larger PROCAS2 study (NCT04359420), 5901 women were offered standard NHSBSP or BC-Predict at the invitation to NHSBSP. Women who took up BC-Predict received 10-year risk estimates: “high” (≥8%), “above average (moderate)” (5–7.99%), “average” (2–4.99%) or “below average (low)” (<2%) risk. A subset of 662 women completed questionnaires at baseline and at 3 months (n = 511) and 6 months (n = 473).
Results
State anxiety and cancer worry scores were low with no differences between women offered BC-Predict or NHSBSP. Women offered BC-Predict and informed of being at higher risk reported higher risk perceptions and cancer worry than other women, but without reaching clinical levels.
Conclusions
Concerns that risk-stratified screening will produce harm due to increases in general anxiety or cancer worry are unfounded, even for women informed that they are at high risk.
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Cancer Research UK. Breast cancer diagnosis and treatment statistics. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer#heading-Zero (Retrieved 25 May 2022).
2. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–86.
3. Evans DG, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, et al. Assessing individual breast cancer risk within the UK National Health Service Breast Screening Programme: a new paradigm for cancer prevention. Cancer Prev Res. 2012;5:943–951.
4. National Institute of Health and Clinical Excellence. Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. NICE Clinical Guideline 164, 2013.
5. Evans DG, Brentnall AR, Harvie M, Dawe S, Sargeant JC, Stavrinos P, et al. Breast cancer risk in young women in the National Breast Screening Programme: implications for applying NICE guidelines for additional screening and chemoprevention. Cancer Prev Res. 2014;7:993–1001.